Although Gefitinib is not the first-line treatment of NSCLC without EGFR mutation, we observed that drug sensitivity also increased when combined with WZB117 treatment in H1299 (Fig. 6H, I). This evidence concerns the gene EGFR and non-small cell lung carcinoma.